Prevalence, pathophysiology, prediction and health-related quality of life of long COVID: study protocol of the longitudinal multiple cohort CORona Follow Up (CORFU) study

Chahinda Ghossein-Doha, Marieke S.J.N. Wintjens, Emma B.N.J. Janssen, Dorthe Klein, Stella C.M. Heemskerk, Folkert W. Asselbergs, Erwin Birnie, Gouke J. Bonsel, Bas C.T. van Bussel, Jochen W.L. Cals, Hugo Ten Cate, Juanita Haagsma, Bena Hemmen, Iwan C.C. van der Horst, Bastiaan L.J.H. Kietselaer, Frederikus A. Klok, Martijn D. de Kruif, Marijke Linschoten, Susanne van Santen, Kevin VernooyLoes H. Willems, Rosa Westerborg, Michiel Warle, Sander M.J. van Kuijk*

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: ArticleAcademicpeer review

5 Downloads (Pure)


INTRODUCTION: The variety, time patterns and long-term prognosis of persistent COVID-19 symptoms (long COVID-19) in patients who suffered from mild to severe acute COVID-19 are incompletely understood. Cohort studies will be combined to describe the prevalence of long COVID-19 symptoms, and to explore the pathophysiological mechanisms and impact on health-related quality of life. A prediction model for long COVID-19 will be developed and internally validated to guide care in future patients. METHODS AND ANALYSIS: Data from seven COVID-19 cohorts will be aggregated in the longitudinal multiple cohort CORona Follow Up (CORFU) study. CORFU includes Dutch patients who suffered from COVID-19 at home, were hospitalised without or with intensive care unit treatment, needed inpatient or outpatient rehabilitation and controls who did not suffer from COVID-19. Individual cohort study designs were aligned and follow-up has been synchronised. Cohort participants will be followed up for a maximum of 24 months after acute infection. Next to the clinical characteristics measured in individual cohorts, the CORFU questionnaire on long COVID-19 outcomes and determinants will be administered digitally at 3, 6, 12, 18 and 24 months after the infection. The primary outcome is the prevalence of long COVID-19 symptoms up to 2 years after acute infection. Secondary outcomes are health-related quality of life (eg, EQ-5D), physical functioning, and the prevalence of thromboembolic complications, respiratory complications, cardiovascular diseases and endothelial dysfunction. A prediction model and a patient platform prototype will be developed. ETHICS AND DISSEMINATION: Approval was obtained from the medical research ethics committee of Maastricht University Medical Center+ and Maastricht University (METC 2021-2990) and local committees of the participating cohorts. The project is supported by ZonMW and EuroQol Research Foundation. Results will be published in open access peer-reviewed scientific journals and presented at (inter)national conferences. TRIAL REGISTRATION NUMBER: NCT05240742.

Originele taal-2English
Aantal pagina's15
TijdschriftBMJ Open
Nummer van het tijdschrift11
StatusPublished - 29-nov.-2022

Citeer dit